Heron Therapeutics HRTX shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.
Heron Therapeutics is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.
Heron Therapeutics’s shares were up 0.49% at $18.53 at the time of publication. The stock has a 52-week high of $26.81 and a 52-week low of $9.60.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
